罗氏制药公开表示反对诺和诺德收购合同药品生产商康泰伦特,认为这将限制减肥药领域的竞争,不利于行业发展。罗氏首席执行官托马斯-施奈德指出,如果这笔交易获得批准,将对蓬勃发展的减肥药行业产生不利影响。
除罗氏外,礼来、阿斯利康等制药巨头均对该交易表示担忧,认为康泰伦特是许多公司减肥药产品的重要生产商。一旦被诺和诺德收购,市场竞争力可能受到削弱。一些小型生物技术公司如Viking Therapeutics、Structure Therapeutics等,在生产和供应肥胖症药物方面也可能受到影响。
一个由消费者、患者和工人权益组织组成的联盟已向美国联邦贸易委员会提出申请,要求阻止该交易。该联盟认为,交易一旦获批,不仅将威胁减肥药市场竞争,基因疗法领域亦可能受到冲击。不过,诺和诺德方面回应称,即使收购康泰伦特,市场上仍有大量其他合同药品生产商可供选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.